Inflammatory disease Archives

News and Trends 5 Dec 2022

First subject dosed in inflammation phase I study

Innovent Biologics, Inc. and UNION therapeutics A/S have announced that the first Chinese healthy volunteer has been successfully dosed in the phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical phase II stage. This study is a multiple dose escalation phase I study in healthy volunteers aiming to evaluate the pharmacokinetic […]

December 5, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

More News! 18 Nov 2022

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis. “We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients,” […]

November 18, 2022 - 2 minutesmins - By Jim Cornall

More News! 14 Nov 2022

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and new formulations adapted to a significant number of important indications with unmet medical needs. BioSenic specializes in serious autoimmune and inflammatory diseases as well as cell repair. The update follows the announcement of the merger between Bone Therapeutics and Medsenic […]

November 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide

EpiEndo Pharmaceuticals, a clinical-stage biopharma company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to begin a phase 2a clinical trial. The trial will be with lead molecule EP395 in COPD (chronic obstructive pulmonary disease) patients, an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential. It aims to address the unmet […]

November 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Researchers develop new nanoparticle to deliver drugs direct to macrophages

How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to […]

November 10, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Lipum starts chronic inflammatory disease drug study

Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […]

November 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Oct 2022

Delayed release tablets to treat ulcerative colitis launched in Canada

With Canada having one of the highest incidences of ulcerative colitis in the world, the recent launch of Tillotts Pharma AG’s Octasa 800 mg will be well-received. Tillotts is part of the Japanese Zeria Group, and announced Octasa (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada. The launch, the […]

October 25, 2022 - 2 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

C4XD and HitGen to collaborate on inflammation hit identification project

Drug discovery company C4X Discovery Holdings plc and HitGen Inc., which develops DNA-encoded library (DEL) technology, are to collaborate on identifying novel, small molecule hits against an inflammatory target for further C4XD development. The aim of the project is to augment C4XD’s pipeline of small molecule inflammatory disease candidates for pre-clinical development and out-licensing to […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Sep 2022

NodThera reveals positive results for inflammasome inhibitors

Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249. A phase 1 study has been completed for NT-0796, confirming brain penetration with excellent pharmacokinetic (PK) and pharmacodynamic (PD) profiles and for NT-0249, dosing of the phase 1 single ascending dose cohorts has been completed, […]

September 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

Cyxone receives approval for phase 2b rheumatoid arthritis study

Swedish biotech company Cyxone has received approval from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is […]

September 19, 2022 - 2 minutesmins - By Jim Cornall

lupus autoimmune disease neutrophil citryll

News and Trends 16 Sep 2022

Domainex’ drug shows positive data for treatment of interferonopathies

Interferonapathies such as lupus, Sjögren’s syndrome, and scleroderma could be treated effectively after positive human ex-vivo data was produced. Domainex Ltd., carried out an in-house research program to identify inhibitors of protein kinases TBK1 and IKK-epsilon and DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. Disease modifying The […]

September 16, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us